MRK
MRNA
The science says “nice,” the stock says “meh”
Moderna spent Monday waving around some pretty strong five-year follow-up data from its melanoma trial with Merck, and the market response was basically a shrug with a side of selling. Because apparently even a 49% drop in recurrence or death risk isn’t enough to make traders stop acting like it’s a group project where nobody wants to do the presentation.
The data came from the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of intismeran autogene (mRNA-4157/V940) plus Keytruda in high-risk stage III/IV melanoma after surgery. After a median follow-up of 60.3 months, the combo still showed durable benefit, including a 59% reduction in distant metastasis or death versus Keytruda alone.
Why investors are paying attention
This matters because Moderna’s whole post-COVID identity crisis has been: can the mRNA platform become more than a one-hit wonder? Cancer vaccines are one of the biggest answers to that question. If this program keeps delivering, it gives the company a lot more than just pandemic nostalgia and flu-shot ambitions.
But the market is moody, and this stock has been living in the “show me the revenue” era for a while. Good clinical data helps, sure — but investors also want to know when those biology wins turn into actual dollars instead of just nicer conference slides.
Bonus plot twist: Ebola enters the chat
As if one biotech storyline wasn’t enough, Moderna also expanded its partnership with CEPI to develop a vaccine against the Bundibugyo ebolavirus. CEPI said it could commit up to $50 million to help fund preclinical work and Phase 1 testing, plus some manufacturing in parallel so the program can move faster if the early data cooperate.
That’s not the kind of deal that moves the needle overnight, but it does add another shot on goal for Moderna’s platform. And in biotech, more shots on goal is often the closest thing to a business model.
Big picture: Moderna just reminded the market that it still has real science under the hood. The problem is that Wall Street isn’t grading on effort — it wants the path from “promising data” to “actual blockbuster” to be a little less foggy.